Co-amplification of phosphoinositide 3-kinase enhancer A and cyclin-dependent kinase 4 triggers glioblastoma progression

• Type of Material: Article
• Authors: Qi Qi, Emory University; Seong-Su Kang, Emory University; Shuai Zhang, Emory University; Cau Pham, Emory University; Haian Fu, Emory University; Daniel Brat, Emory University; Keqiang Ye, Emory University
• Language: English
• Date: 2017-08-10
• Publisher: Nature Publishing Group
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved
• Final Published Version (URL): http://dx.doi.org/10.1038/onc.2017.67
• Title of Journal or Parent Work: Oncogene
• ISSN: 0950-9232
• Volume: 36
• Issue: 32
• Start Page: 4562
• End Page: 4572
• Grant/Funding Information: This work has been funded in part with Federal funds from National Cancer Institute (NCI), National Institutes of Health (NIH), under the NCI Chemical Biology Consortium Contract HHSN261200800001E (H.F.; K.Y.), NIH grant RO1 CA186918 (K.Y.), U01 CA168449 (H.F.), SBTF Foundation (K.Y), National Natural Science Foundation of China (No.81672781).
• Keywords: Cell Biology; PIKE-A; INHIBITION; Life Sciences & Biomedicine; INVASION; CDK4; MDM2; GENE; AMPLIFICATION; AKT; GTPASE; Biochemistry & Molecular Biology; Genetics & Heredity; Oncology; PATHWAYS; Science & Technology

Abstract

Glioblastoma (GBM) is the most common primary brain tumor and has a dismal prognosis. Amplification of chromosome 12q13-q15 (Cyclin-dependent kinase 4 (CDK4) amplicon) is frequently observed in numerous human cancers including GBM. Phosphoinositide 3-kinase enhancer (PIKE) is a group of GTP-binding proteins that belong to the subgroup of centaurin GTPase family, encoded by CENTG1 located in CDK4 amplicon. However, the pathological significance of CDK4 amplicon in GBM formation remains incompletely understood. In the current study, we show that co-expression of PIKE-A and CDK4 in TP53/PTEN double knockout GBM mouse model additively shortens the latency of glioma onset and survival compared to overexpression of these genes alone. Consequently, p-mTOR, p-Akt and p-ERK pathways are highly upregulated in the brain tumors, in alignment with their oncogenic activities by CDK4 and PIKE-A stably transfected in GBM cell lines. Hence, our findings support that PIKE amplification or overexpression coordinately acts with CDK4 to drive GBM tumorigenesis.